Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Sanara MedTech (SMTI) over the last 11 years, with Q3 2025 value amounting to $18.3 million.

  • Sanara MedTech's Asset Writedowns and Impairment rose 1885599.48% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 341002.77%. This contributed to the annual value of $624448.0 for FY2024, which is 5349.79% up from last year.
  • Sanara MedTech's Asset Writedowns and Impairment amounted to $18.3 million in Q3 2025, which was up 1885599.48% from $172679.0 recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Asset Writedowns and Impairment registered a high of $18.3 million during Q3 2025, and its lowest value of $7312.0 during Q1 2021.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $145003.0 (2021), whereas its average is $1.1 million.
  • In the last 5 years, Sanara MedTech's Asset Writedowns and Impairment tumbled by 7562.67% in 2021 and then skyrocketed by 1885599.48% in 2025.
  • Sanara MedTech's Asset Writedowns and Impairment (Quarter) stood at $145003.0 in 2021, then surged by 72.88% to $250684.0 in 2022, then decreased by 26.55% to $184121.0 in 2023, then soared by 45.66% to $268187.0 in 2024, then soared by 6733.82% to $18.3 million in 2025.
  • Its Asset Writedowns and Impairment was $18.3 million in Q3 2025, compared to $172679.0 in Q2 2025 and $199278.0 in Q1 2025.